New Study Suggests Dalfampridine May Improve Information Processing Speed in People With National Multiple Sclerosis Society
July 31, 2019
July 31, 2019
NEW YORK, July 31 -- The National Multiple Sclerosis Society issued the following news:
* * *
- Dalfampridine tablets (Ampyra(R), Acorda Therapeutics) improved cognition involving information processing speed in a controlled clinical trial involving 120 people with MS. Ampyra is a symptomatic therapy that is approved by the FDA to improve walking in people with MS.
- In an accompanying editorial, the authors note that the study provides strong evidence for . . .
* * *
- Dalfampridine tablets (Ampyra(R), Acorda Therapeutics) improved cognition involving information processing speed in a controlled clinical trial involving 120 people with MS. Ampyra is a symptomatic therapy that is approved by the FDA to improve walking in people with MS.
- In an accompanying editorial, the authors note that the study provides strong evidence for . . .